Company* (Country; Symbol) |
Company* |
Type/Product Area |
Terms/Details (Date) |
| |||
Affymetrix Inc. (AFFX) |
Caliper Technologies Corp. (CALP) |
Collaboration to develop and provide automated target preparation instruments for GeneChip and other products |
New products will incorporate Caliper's expertise in high-throughput automation and microfluidics with Affymetrix's expert- ise in microarray technology; Affymetrix would market resulting products (1/13) |
|
|||
Argenta Discovery Ltd.* (UK) |
TTP LabTech (unit of TTP Group plc; UK) |
Deal to expand Argenta's capabilities through the incorporation of TTP's Acumen Explorer screening platform |
The companies also will work to develop novel screening assays within the drug dis- covery process (1/29) |
|
|||
CombiMatrix Group (CMBX) |
Cyrano Sciences Inc.* |
Collaboration on the development of chemical sensors that merge CombiMatrix's microarray technology with Cyrano's electronic nose technology |
They intend to develop products for sensing chemical agents in air and water; terms were not disclosed (1/12) |
|
|||
Concurrent Pharmaceuticals Inc.* |
Intel Corp. |
Collaboration to apply machine learning tools to the discovery and development of drugs |
Intel Capital was among the investors in Concurrent's Series B financing, which was disclosed along with the alliance; terms of the deal were not disclosed (1/12) |
|
|||
PharmaStem Therapeutics Inc.* |
Securacell Inc.* |
Securacell gained a license to PharmaStem patents |
Securacell will use the patents in its umbilical cord blood-banking business (2/5) |
|
|||
PharmaStem Therapeutics Inc.* |
Newborn Blood Banking Inc.* |
Newborn Blood Banking gained a license to PharmaStem's patent portfolio |
The patents are in the area of umbilical cord and placental blood preservation; terms were not disclosed (1/30) |
|
|||
| |||
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, the trading symbols listed for public companies are on the Nasdaq market. |